a.org/","@type":"MusicRecording","@id":"https://play.anghami.com/song/1217972819","url":"https://play.anghami.com/song/1217972819","name":"Julia Mayerle on the validation of plasma multimetabolite signatures for patients at risk of or with suspected pancreatic ductal adenocarcinoma","description":"The Lancet Gastroenterology & Hepatology in conversation with · Episode · 2025","datePublished":"2025-06-19","image":"https://artwork.anghcdn.co/webp/?id=229477200&size=640","byArtist":{"@type":"MusicGroup","name":"The Lancet Group"},"inAlbum":{"@type":"MusicAlbum","name":"The Lancet Gastroenterology & Hepatology in conversation with"},"potentialAction":{"@type":"ListenAction","target":[{"@type":"EntryPoint","urlTemplate":"https://play.anghami.com/song/1217972819?autoplay=true","actionPlatform":["http://schema.org/DesktopWebPlatform","http://schema.org/IOSPlatform","http://schema.googleapis.com/GoogleAudioCast","http://schema.googleapis.com/GoogleVideoCast"]},"android-app://com.anghami/song/ 1217972819?autoplay=true"],"expectsAcceptanceOf":{"@type":"Offer","category":"free"}}}1c:T4b3,

Can a multi-metabolite blood test improve early pancreatic cancer detection? We spoke to Julia Mayerle about the METAPAC study, which sought to validate the ability of plasma metabolic signatures to find resectable tumors and reduce unnecessary invasive procedures in high-risk patients.

Read the full article:

https://www.thelancet.com/journals/langas/article/PIIS2468-1253(25)00056-1/fulltext?dgcid=buzzsprout_icw_podcast_June_25_langas

Continue this conversation on social!

https://bsky.app/profile/lancetgastrohep.bsky.social

https://www.linkedin.com/company/langastro/

Julia Mayerle on the validation of plasm...